Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review

被引:0
|
作者
Nasimi, Nasratullah [1 ]
Nasimi, Safiullah [1 ]
Grauslund, Jakob [1 ,2 ,3 ,4 ]
Vergmann, Anna Stage [1 ,2 ]
Subhi, Yousif [2 ,5 ,6 ]
机构
[1] Odense Univ Hosp, Dept Ophthalmol, Odense, Denmark
[2] Univ Southern Denmark, Dept Clin Res, Campusvej 55, DK-5230 Odense, Denmark
[3] Odense Univ Hosp, Steno Diabet Ctr Odense, Odense, Denmark
[4] Vestfold Hosp Trust, Dept Ophthalmol, Tonsberg, Norway
[5] Rigshosp, Dept Ophthalmol, Copenhagen, Denmark
[6] Zealand Univ Hosp, Dept Ophthalmol, Roskilde, Denmark
关键词
Age-related macular degeneration; Faricimab; Efficacy; Real-world evidence; Systematic review;
D O I
10.1186/s40942-024-00566-0
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
BackgroundTo systematically review the real-world outcomes of intravitreal faricimab treatment in patients with neovascular age-related macular degeneration (nAMD) to evaluate its efficacy and safety in clinical settings. This study was conducted due to the need for real-world evidence to complement the findings from controlled clinical phase-III trials.MethodsA systematic literature search was conducted on March 17, 2024, across 11 databases, utilizing search terms specifically tailored each database. All studies were reviewed qualitatively with specific focus on the outcomes of interest: the best-corrected visual acuity (BCVA), the central retina thickness (CRT), and the burden of therapy.ResultsWe identified a total of 22 eligible studies of 1762 eyes from 1618 patients with nAMD. Studies reported that intravitreal faricimab injections maintained BCVA in patients with previously treated eyes and demonstrated statistically significant improvement in patients with treatment-na & iuml;ve eyes. The CRT was reduced after intravitreal faricimab therapy. Faricimab was well-tolerated, with no significant safety concerns identified, and reduced the overall burden of therapy.ConclusionReal-world studies corroborate the conclusions drawn from phase-III trials regarding faricimab treatment, demonstrating improvement in both visual and anatomical outcomes. Additionally, no significant safety issues were identified, as the treatment was generally well-tolerated and reduced the overall burden of therapy in the real-world settings.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept
    Machida, Akira
    Oishi, Akio
    Ikeda, Junichiro
    Kurihara, Junko
    Yoneda, Ai
    Tsuiki, Eiko
    Hirata, Yuki
    Murakami, Ryuya
    Kitaoka, Takashi
    [J]. LIFE-BASEL, 2024, 14 (04):
  • [42] Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration
    Mehta, Neesurg
    Fong, Rodney
    Wilson, Machelle
    Moussa, Kareem
    Emami-Naeini, Parisa
    Moshiri, Ala
    Yiu, Glenn
    Park, Susanna S.
    [J]. CLINICAL OPHTHALMOLOGY, 2023, 17 : 657 - 665
  • [43] Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration
    Brynskov, Troels
    Munch, Inger Christine
    Larsen, Tobias Malte
    Erngaard, Iiv
    Sorensen, Torben Lykke
    [J]. ACTA OPHTHALMOLOGICA, 2020, 98 (02) : 132 - 138
  • [44] Consequences of Real-World Surveillance of Fellow Eyes in Neovascular Age-Related Macular Degeneration
    Onwuka, Oluchukwu
    Saddemi, Jackson L.
    Aydogmus, Fatma Sema Akkan
    Lasalle, Claudia C.
    Ramsey, David J.
    [J]. LIFE-BASEL, 2023, 13 (02):
  • [45] Consequences of Real-world Surveillance of Fellow Eyes in Neovascular Age-related Macular Degeneration
    Onwuka, Oluchukwu
    Saddemi, Jackson
    Akkan, F. Sema
    Lasalle, Claudia
    Ramsey, David J.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [46] Short-term safety and efficacy of intravitreal brolucizumab injections for neovascular age-related macular degeneration: a multicenter retrospective real-world study
    Kim, Dong Ju
    Jin, Ki Won
    Han, Jeong Mo
    Lee, Seung Hyun
    Park, Yong Seok
    Lee, Joo Yong
    Lee, Eun Kyoung
    Lee, Jun Sung
    Kim, Seong Taeck
    Shin, Min Ho
    Lee, Christopher Seungkyu
    Jung, Hyun Ho
    Jang, Jae Yong
    Kim, Min
    Kim, Yung Hui
    Kim, Jae Hui
    Park, Kyu Hyung
    Park, Sang Jun
    Joo, Kwangsic
    Ji, Yong Sok
    Sagong, Min
    Woo, Se Joon
    [J]. OPHTHALMOLOGICA, 2023, 246 (3-4) : 192 - 202
  • [47] RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A Systematic Review of Real-World Evidence
    Wykoff, Charles C.
    Matsumoto, Hidetaka
    Barakat, Mark R.
    Karcher, Helene
    Lozama, Anthony
    Mayhook, Andrew
    Oshagbemi, Olorunfemi A.
    Zorina, Olessia
    Hassan, Tarek S.
    Khanani, Arshad M.
    Heier, Jeffrey S.
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2023, 43 (07): : 1051 - 1063
  • [48] Changes in Macular Pigment Optical Density after Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration: A Pilot Study
    Cennamo, Gilda
    Rinaldi, Michele
    Chiosi, Flavia
    Costagliola, Ciro
    [J]. JOURNAL OF CLINICAL MEDICINE, 2024, 13 (16)
  • [49] Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
    Liberski, Slawomir
    Wichrowska, Malgorzata
    Kociecki, Jaroslaw
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (16)
  • [50] A SYSTEMATIC REVIEW AND META-ANALYSIS OF REAL-WORLD EVIDENCE STUDIES OF INTRAVITREAL AFLIBERCEPT IN WET AGE-RELATED MACULAR DEGENERATION
    Yoon, J.
    Bouwmeester, W.
    Chuang, L.
    Carrasco, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S422 - S422